BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

Healthcare Biotechnology

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp.

<< Previous

Bullboard Posts

Next >>

Post by frankmanon Dec 20, 2024 3:53pm

32 Views

Post# 36372851

2.3 mil shares traded 1 mil $US OTC .065

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr
ATS	13.0	0.06	·	0.065	29.0	0.065	+0.005	8.3	1,279.0	76	90
CSE - C	13.0	0.06	·	0.065	29.0	0.065	+0.005	8.3	686.5	41	39
NEO ATS - U						0.065	+0.005	8.3	11.0	1	2
Omega - O						0.065	+0.005	8.3	321.0	19	20
CX2 - H						0.065	+0.005	8.3	213.0	13	17
CXD - D						0.06			1.4		3
TriAct - M						0.06			28.1	1	8
CS2 - S						0.065	+0.005	8.3	18.0	1	1